Skip to main content

2022 CTOS Annual Meeting Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Tom Andor, n/a

Cogent Biosciences

Poster(s):

(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS